Hayashi, Kenichi

写真a

Affiliation

Faculty of Science and Technology, Department of Mathematics （Yagami）

Position

Associate Professor
Page Top ▲
 

Research Areas 【 Display / hide 】

  • Statistical science

Page Top ▲
 

Books 【 Display / hide 】

  • Rで学ぶ統計的データ解析

    林 賢一, 講談社サイエンティフィク, 2020.11,  Page： 352

  • Machine Learning: The Art and Science of Algorithms that Make Sense of Data

    竹村彰通（監訳），田中研太郎，小林景，兵頭昌，片山翔太，山本倫生，吉田拓真，林賢一，松井秀俊，小泉和之，永井勇, 朝倉書店, 2017.04

    Scope: 7章

Page Top ▲

Papers 【 Display / hide 】

  • Pulmonary vein isolation alone vs. more extensive ablation with defragmentation and linear ablation of persistent atrial fibrillation: the EARNEST-PVI trial

    Inoue K., Hikoso S., Masuda M., Furukawa Y., Hirata A., Egami Y., Watanabe T., Minamiguchi H., Miyoshi M., Tanaka N., Oka T., Okada M., Kanda T., Matsuda Y., Kawasaki M., Hayashi K., Kitamura T., Dohi T., Sunaga A., Mizuno H., Nakatani D., Sakata Y.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology （Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology)  23 （ 4 ） 565 - 574 2021.04

    ISSN  10995129

    　View Summary

    AIMS: Previous studies could not demonstrate any benefit of more intensive ablation in addition to pulmonary vein isolation (PVI) including complex fractionated atrial electrogram (CFAE) and linear ablation for recurrence in the initial catheter ablation of persistent atrial fibrillation (AF). This study aimed to establish the non-inferiority of PVI alone to PVI plus these additional ablation strategies. METHODS AND RESULTS: Patients with persistent AF who underwent an initial catheter ablation (n = 512, long-standing persistent AF; 128 cases) were randomly assigned in a 1:1 ratio to either PVI alone (PVI-alone group) or PVI plus CFAE and/or linear ablation (PVI-plus group). After excluding 15 cases who did not receive procedures, we analysed 249 and 248 patients, respectively. The primary endpoint was recurrence of AF, atrial flutter, and/or atrial tachycardia, and the non-inferior margin was set at a hazard ratio of 1.43. In the PVI-plus group, 85.1% of patients had linear ablation and 15.3% CFAE ablation. After 12 months, freedom from the primary endpoint occurred in 71.3% of patients in the PVI-alone group and in 78.3% in the PVI-plus group [hazard ratio = 1.56 (95% confidence interval: 1.10-2.24), non-inferior P = 0.3062]. The procedure-related complication rates were 2.0% in the PVI-alone group and 3.6% in the PVI-plus group (P = 0.199). CONCLUSION: This randomized trial did not establish the non-inferiority of PVI alone to PVI plus linear ablation or CFAE ablation in patients with persistent AF, but implied that the PVI plus strategy was promising to improve the clinical efficacy (NCT03514693).

  • A nationwide randomized, double-blind, placebo-controlled physicians’ trial of loxoprofen for the treatment of fatigue, headache, and nausea after hangovers

    Hara M., Hayashi K., Kitamura T., Honda M., Tamaki M.

    Alcohol （Alcohol)  84   21 - 25 2020.05

    ISSN  07418329

    　View Summary

    Hangovers are associated with negative economic consequences due to decreased job performance or frequent visits to physicians. Thus, a new strategy for the alleviation of hangover-related symptoms is needed to avoid this detriment to society. The purpose of this nationwide randomized, double-blind, placebo-controlled physicians’ trial was to evaluate the efficacy of loxoprofen sodium for the alleviation of fatigue, headache, and nausea after hangover. A total of 229 participants were randomized to receive loxoprofen sodium (60 mg once orally) or placebo. The study was closed when the first 150 participants (n = 74 in the loxoprofen vs. n = 76 in the placebo groups) experienced hangovers. The primary endpoint was set as the difference in severity of general fatigue before and 3 h after taking the test drugs and was evaluated using a visual analogue scale. Secondary endpoints included difference in severity of headache, nausea, and incidence of adverse events. The study participants were 34 (interquartile range; 30–39) years old, 92.0% were men, and both groups were comparable for baseline characteristics. The alleviation of general fatigue did not differ statistically between the loxoprofen and placebo groups (24 [14–49] vs. 19 [9–35], p = 0.07). However, the alleviation of headache was statistically greater in the loxoprofen group (25 [10–50] vs. 10 [2–30], adjusted difference 14, 95% confidence interval 8–21, p < 0.001), whereas, there was no difference in nausea (7 [0–27] vs. 10 [0–24], p = 0.68). The incidence of adverse symptoms such as epigastric discomfort was also comparable between groups (2.7% vs. 3.9%, p = 0.25). Loxoprofen sodium was effective for relieving headaches after hangovers but did not alleviate general fatigue or nausea.

  • Effect of Extensive Ablation on Recurrence in Patients with Persistent Atrial Fibrillation Treated with Pulmonary Vein Isolation (EARNEST-PVI) trial: Design and rationale

    Dohi T., Nakatani D., Inoue K., Hikoso S., Oka T., Hayashi K., Masuda M., Furukawa Y., Kawasaki M., Egami Y., Kashiwase K., Hirata A., Watanabe T., Miyoshi M., Takeda T., Nakagawa A., Mizuno H., Minamiguchi H., Kitamura T., Suna S., Kojima T., Kida H., Bolrathanak O., Okuyama Y., Sakata Y.

    Journal of Cardiology （Journal of Cardiology)  74 （ 2 ） 164 - 168 2019.08

    ISSN  09145087

    　View Summary

    Background: Although extensive substrate modification in addition to pulmonary vein isolation (PVI) has been recommended in catheter ablation for persistent atrial fibrillation (AF), recent randomized controlled trials have not demonstrated efficacy of such additional ablations. Methods and study design: The Osaka Cardiovascular Conference will conduct a multicenter, randomized, open-label trial aiming to examine whether PVI alone is non-inferior to PVI plus additional ablation such as linear ablation and/or complex fractionated atrial electrogram ablation in patients with persistent AF. The primary outcome is recurrence of AF documented by scheduled or symptom-driven electrocardiogram tests during a 1-year follow-up period after the index ablation. The key secondary endpoints include all-cause death, occurrence of symptomatic stroke, complications related to the procedure, and quality of life assessment using the 36-item Short-Form Health Survey. The clinical impact of the presence or absence of AF trigger foci, and their origins in cases with them, on the results of catheter ablation will also be investigated as an exploratory endpoint. A total of 512 patients will be enrolled and followed up to 1 year. Conclusions: The EARNEST-PVI trial is a randomized controlled trial designed to assess whether PVI alone is non-inferior to extended substrate ablation for patients with persistent AF undergoing a first catheter ablation.

  • The power-integrated discriminant improvement: An accurate measure of the incremental predictive value of additional biomarkers

    Hayashi K., Eguchi S.

    Statistics in Medicine （Statistics in Medicine)  38 （ 14 ） 2589 - 2604 2019.06

    ISSN  02776715

    　View Summary

    The predictive performance of biomarkers is a central concern in biomedical research. This is often evaluated by comparing two statistical models: a “new” model incorporating additional biomarkers and an “old” model without them. In 2008, the integrated discrimination improvement (IDI) was proposed for cases when the response variable is binary, and it is now widely applied as a promising alternative to conventional measures, such as the difference of the area under the receiver operating characteristic curve. However, the IDI can erroneously identify a significant improvement in the new model even if no additional information has been provided by new biomarkers. In order to overcome problems with existing measures, in this study, we propose the power-IDI as a measure of incremental predictive value. Our study explains why the IDI cannot avoid false detection of apparent improvements in a new model and we show that our proposed measure is better able to capture improvements in prediction. Numerical simulations and examples using real empirical data reveal that the power-IDI is not only more powerful but also incurs fewer false detections of improvement.

  • Asymptotic comparison of semi-supervised and supervised linear discriminant functions for heteroscedastic normal populations

    Hayashi K.

    Advances in Data Analysis and Classification （Advances in Data Analysis and Classification)  12 （ 2 ） 215 - 339 2018.07

    ISSN  18625347

    　View Summary

    It has been reported that using unlabeled data together with labeled data to construct a discriminant function works successfully in practice. However, theoretical studies have implied that unlabeled data can sometimes adversely affect the performance of discriminant functions. Therefore, it is important to know what situations call for the use of unlabeled data. In this paper, asymptotic relative efficiency is presented as the measure for comparing analyses with and without unlabeled data under the heteroscedastic normality assumption. The linear discriminant function maximizing the area under the receiver operating characteristic curve is considered. Asymptotic relative efficiency is evaluated to investigate when and how unlabeled data contribute to improving discriminant performance under several conditions. The results show that asymptotic relative efficiency depends mainly on the heteroscedasticity of the covariance matrices and the stochastic structure of observing the labels of the cases.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 異質な集団を含むデータに対する統計的学習理論を用いたモデル開発と臨床医学への応用

    2018.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 林　賢一, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • A study on exploratory identification of responsive subgroups in complex survival event data

    2015.04
    -
    2018.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 林　賢一, Grant-in-Aid for Young Scientists (B), Principal Investigator

Page Top ▲

Awards 【 Display / hide 】

  • 若手優秀発表賞

    2021.05, 日本計量生物学会

    Type of Award： Awards of National Conference, Council and Symposium

    　View Description

    2021年度計量生物学会年会 若手優秀発表賞（正会員の部）

  • 最優秀賞

    奥富航，林賢一, 2018.01, 第7回スポーツデータ解析コンペティション審査会, 第7回スポーツデータ解析コンペティション

    Type of Award： Other Awards

    　View Description

    奥富航（理工学部数理科学科，筆頭著者）との共同研究

  • 論文賞

    2017.12, 日本分類学会, 日本分類学会

    Type of Award： Awards of National Conference, Council and Symposium

  • 論文賞

    2015.05, 日本計算機統計学会, 日本計算機統計学会

    Type of Award： Awards of National Conference, Council and Symposium

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • SEMINAR IN STATISTICAL SCIENCES

    2021

  • LINEAR ALGEBRA

    2021

  • INTRODUCTION TO STATISTICAL SCIENCE

    2021

  • INDEPENDENT STUDY ON FUNDAMENTAL SCIENCE AND TECHNOLOGY

    2021

  • GRADUATE RESEARCH ON FUNDAMENTAL SCIENCE AND TECHNOLOGY 2

    2021

display all >>

Page Top ▲